CorVent Launches AI/ML-Driven CorVision, Opens Series B

CorVent Medical, a company applying artificial intelligence (AI) and machine learning (ML) to improve outcomes for critically ill, ventilated patients, has launched its CorVision intelligent ventilation software platform. The company also opened its Series B financing round.

This follows the commercial success of its Respond ventilator and over $45 million raised through Series A. CorVent is expanding its AI/ML platform strategy, supported by the Series B, to advance critical care decision-making and drive efficiency in intensive care and emergency settings.

The company plans to submit a 510(k) application to the U.S. Food and Drug Administration (FDA) next month. Connected to the Series B, CorVent execs will attend the J.P. Morgan Healthcare Conference in January 2026 and are scheduling meetings with investors and strategic partners.

The CorVision SaaS platform integrates with hospital EMR systems, telemedicine networks, and rural health infrastructures, enabling scalable solutions that strengthen healthcare system resilience and improve ventilator management at the bedside and beyond.

“Critical care teams today face an unprecedented combination of clinical complexity, staffing shortages, and rising patient acuity,” said Richard Walsh, CEO of CorVent. “With CorVision, we are applying advanced predictive intelligence to make ventilation management safer, more efficient, and more accessible-especially in rural and resource-limited healthcare environments.”